Market Research Logo

Global Bladder Cancer Therapeutics Market 2017-2021

Global Bladder Cancer Therapeutics Market 2017-2021

About Bladder Cancer Therapeutics

The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.

Technavio’s analysts forecast the global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global bladder cancer therapeutics market for 2017-2021. To calculate the market size, the report considers the sales from both branded and generic drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffman-La Roche
  • Pfizer
Other prominent vendors
  • Accord Healthcare
  • AstraZeneca
  • Bedford Lab
  • Merck
  • Sanofi
Market driver
  • Growing prevalence rate leads to higher prescription value
  • For a full, detailed list, view our report
Market challenge
  • Economic burden of bladder cancer
  • For a full, detailed list, view our report
Market trend
  • Advent of novel pipeline
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Bladder Cancer Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global bladder cancer therapeutics market: Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, and Pfizer.

Other Prominent Vendors in the market are: Accord Healthcare, AstraZeneca, Bedford Lab, Merck, and Sanofi.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is advent of novel pipeline. The global bladder cancer therapeutics market is expected to grow due to the presence of novel therapies in the early stages of the pipeline. For instance, the adoptive cell therapy utilizes the immunotherapy approach for the treatment of bladder cancer.”

According to the report, one driver in the market is growing prevalence rate leads to higher prescription value. Bladder cancer is the ninth-most type of cancer diagnosed worldwide, with the highest incidence rates demonstrated by males in Southern and Western Europe, North America, and in certain countries in Northern Africa or Western Asia. Bladder cancer ranked among 15 most common causes of deaths worldwide.

Further, the report states that one challenge in the market is economic burden of bladder cancer. Bladder cancer accounts one of the highest treatment cost per patient among all other cancers. The high cost of overall treatment is due to a reoccurrence of the tumor, which requires frequent surgical procedures and lifelong surveillance. The data estimates suggest that more than 50,000 incident cases of bladder cancer were reported in the US in 2007.

Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Pfizer, Accord Healthcare, AstraZeneca, Bedford Lab, Merck, and Sanofi.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
    • Bladder
    • Bladder cancer
    • Currently approved therapeutic regimen
      • Table Approved therapeutics for the treatment of bladder cancer
    • Stages of bladder cancer
      • Table Stages of bladder cancer
  • Key clinical trials
    • Table Pipeline landscape based on development phase 2016
    • Table Key clinical trials
    • Table Snapshot of therapy-based pipeline in global bladder cancer market
  • Market landscape
    • Table Market scenario for global bladder cancer therapeutics market 2016-2021 ($ million)
    • Market size and forecast
      • Table Global bladder cancer therapeutics market revenue 2016-2021 ($ millions)
      • Table Opportunity analysis of global bladder cancer therapeutics market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by therapy
    • Table Segmentation of global bladder cancer therapeutics market by therapy 2016
    • Table Global bladder cancer therapeutics market segmentation based on therapy 2016 (%)
    • Intravesical therapy
      • Table Global bladder cancer therapeutics market for intravesical therapy 2016-2021 ($ millions)
    • Chemotherapy
      • Table Global bladder cancer therapeutics market for chemotherapy 2016-2021 ($ millions)
    • Preservation therapy
      • Table Global bladder cancer therapeutics market for preservation therapy 2016-2021 ($ millions)
    • Others
  • Geographical segmentation
    • Table Segmentation of global bladder cancer therapeutics market based on geography 2016 and 2021
    • Table Global bladder cancer therapeutics market revenue by geography 2016-2021 ($ millions)
    • Table Global bladder cancer therapeutics market share by geography 2016-2021 (%)
    • Bladder cancer therapeutics market in Americas
      • Table Market scenario in Americas
      • Table Bladder cancer therapeutics market in Americas 2016-2021 ($ millions)
    • Bladder cancer therapeutics market in EMEA
      • Table Market scenario in EMEA
      • Table Bladder cancer therapeutics market in EMEA 2016-2021 ($ millions)
    • Bladder cancer therapeutics market in APAC
      • Table Market scenario in APAC
      • Table Bladder cancer therapeutics market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Growing influence of targeted biologics
    • Advent of novel pipeline
    • Emergence of effective diagnostic tools
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global bladder cancer therapeutics market 2016
  • Key vendor analysis
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Key highlights
      • Table Bristol-Myers Squibb: Strength assessment
      • Table Bristol-Myers Squibb: Strategy assessment
      • Table Bristol-Myers Squibb: Opportunity assessment
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
    • F. Hoffman-La Roche
      • Table F. Hoffman-La Roche: Key highlights
      • Table F. Hoffman-La Roche: Strength assessment
      • Table F. Hoffman-La Roche: Strategy assessment
      • Table F. Hoffman-La Roche: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report